Gilead Sciences Inc
NASDAQ: GILD
$89.14
-$1.49 (-1.6%)
Closing Price on January 8, 2025
GILD Articles
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc. (NASDAQ: GILD). This deal is for the discovery and...
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
Published:
Wednesday's top analyst upgrades and downgrades included Agilent Technologies, Cree, Deere, Gilead Sciences, Home Depot, Kohl's, Nordstrom, Walmart and Walt Disney.
Published:
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Published:
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how they...
Published:
The run-up in equity prices related to the COVID-19 outbreak combined with the federal government's efforts to soften the financial damage due to the pandemic have driven equity prices sharply...
Published:
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Gilead has priced its COVID-19 drug candidate at $2,340 for a five-day treatment in the United States and some other developed countries. The company set the price for a single vial of remdesivir at...
Published:
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The new attitude among investors about sustainability and societal impact probably will dominate discussion and investment choices in the years to come. Here are five of RBC's top picks in the arena...
Published:
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.